Computer-aided drug design methodologies toward the design of anti-hepatitis C agents

Current Topics in Medicinal Chemistry

Volumn 12, Issue 8, 2012, Pages 802-813

  Speck Planche, Alejandro ^a,b   Cordeiro, M Natália D S ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDAD DE ORIENTE   (Cuba)

Author keywords

3D QSAR; Anti HCV agents; Fragments; Linear discriminant analysis; QSAR; Structure based drug design

Indexed keywords

ANTIHEPATITIS C AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; HEXAPEPTIDE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; OXOACID; POLYPHENOL DERIVATIVE; UNCLASSIFIED DRUG;

COMPUTER AIDED DESIGN; COMPUTER MODEL; DISCRIMINANT ANALYSIS; DRUG DESIGN; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; THREE DIMENSIONAL IMAGING;

ANTIVIRAL AGENTS; COMPUTER-AIDED DESIGN; DRUG DESIGN; HEPACIVIRUS; HEPATITIS C; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860286484     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612800166783     Document Type: Review

References (133)

1. Champoux, J.J.; Neidhardt, F.C.; Drew, W.L.; Plorde, J.J. In: Sherris Medical Microbiology, 4th ed.; Ryan, K.J.; Ray, C.G. Eds. McGraw Hill: 2004; pp 551-552.
2. Lavanchy, D. Public health measures in the control of viral hepatitis: a World Health Organization perspective for the next millennium. J. Gastroen. Hepatol., 2002, 17(Suppl), S452-459.
3. Cordeiro, M.N.D.S.; Borges, F.; Morales Helguera, A. Bridging Chemical and Biological Space: QSAR Probing using 3D Molecular Descriptors. In Recent Trends on QSAR in the Pharmaceutical Perceptions, Khan, M.T.H., Ed. Bentham Science Publishers: 2012. In Press.
4. Kamal, S.M. Acute hepatitis C: a systematic review. Am. J. Gastroenterol., 2008, 103, 1283-1297.
5. Frank, C.; Mohamed, M.; Strickland, G.; Lavanchy, D.; Arthur, R.; Magder, L.; Khoby, T.; Abdel-Wahab, Y.; Ohn, E.; Anwar, W. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet, 2000, 355, 887-891.
6. Falconer, K.; Sandberg, J.K.; Reichard, O.; Alaeus, A. HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatment. Scandinavian J. Infect. Dis., 2009, 41, 881-885.
7. Klaus, W.; Gsell, B.; Labhardt, A.M.; Wipf, B.; Senn, H. The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J. Mol. Biol., 1997, 274, 661-675.
8. Lagging, M.; Langeland, N.; Pedersen, C.; Farkkila, M.; Buhl, M.R.; Morch, K.; Dhillon, A.P.; Alsio, A.; Hellstrand, K.; Westin, J.; Norkrans, G. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology, 2008, 47, 1837-1845.
9. Lagging, M.; Langeland, N.; Pedersen, C.; Farkkila, M.; Buhl, M.R.; Morch, K.; Dhillon, A.P.; Alsio, A.; Hellstrand, K.; Westin, J.; Christensen, P.; Leutscher, P.; Norkrans, G. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology, 2008, 48, 695.
10. Lagging, M.; Wejstal, R.; Uhnoo, I.; Gerden, B.; Fischler, B.; Friman, S.; Josephson, F.; Karlstrom, O.; Sangfelt, P.; Schvarz, R.; Weiland, O. Treatment of hepatitis C virus infection: updated Swedish consensus recommendations. Scandin. J. Infect. Dis., 2009, 41, 389-402.
11. Awad, T.; Thorlund, K.; Hauser, G.; Stimac, D.; Mabrouk, M.; Gluud, C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology, 2010, 51, 1176-1184.
12. Bunin, B.A.; Bajorath, J.; Siesel, B.; Morales, G. Chemoinformatics: Theory, Practice and Products, Springer: Dordrecht, 2007.
13. Oprea, T. Chemoinformatics in Drug Discovery, Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2005.
14. Gasteiger, J. Handbook of Chemoinformatics, Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2003.
15. Larson, R.S. Bioinformatics and Drug Discovery, Humana Press Inc: Totowa, New Jersey, 2006.
16. Hamacher, M.; Marcus, K.; Stühler, K.; van Hall, A.; Warscheid, B.; Meyer, H.E. Proteomics in Drug Research, Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2006.
17. Polanski, A.; Kimmel, M. Bioinformatics, Springer-Verlag: Berlin, Heidelberg, New York, 2007.
18. Zaki, M.J.; Bystroff, C. Protein Structure Prediction, 2nd ed.; Humana Press Inc: Troy, New York, 2008.
19. Caballero, J.; Fernandez, M. Artificial neural networks from MATLAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN): application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1). Curr. Top. Med. Chem., 2008, 8, 1580-1605.
20. Duardo-Sanchez, A.; Patlewicz, G.; Lopez-Diaz, A. Current topics on software use in medicinal chemistry: intellectual property, taxes, and regulatory issues. Curr. Top. Med. Chem., 2008, 8, 1666-1675.
21. Gonzalez, M.P.; Teran, C.; Saiz-Urra, L.; Teijeira, M. Variable selection methods in QSAR: an overview. Curr. Top. Med. Chem., 2008, 8, 1606-1627.
22. Gonzalez-Diaz, H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr. Top. Med. Chem., 2008, 8, 1554.
23. Gonzalez-Diaz, H.; Prado-Prado, F.; Ubeira, F.M. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr. Top. Med. Chem., 2008, 8, 1676-1690.
24. Helguera, A.M.; Combes, R.D.; Gonzalez, M.P.; Cordeiro, M.N.D.S. Applications of 2D descriptors in drug design: a DRAGON tale. Curr. Top. Med. Chem., 2008, 8, 1628-1655.
25. Ivanciuc, O. Weka machine learning for predicting the phospholipidosis inducing potential. Curr. Top. Med. Chem., 2008, 8, 1691-1709.
26. Vilar, S.; Cozza, G.; Moro, S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr. Top. Med. Chem., 2008, 8, 1555-1572.
27. Wang, J.F.; Wei, D.Q.; Chou, K.C. Drug candidates from traditional chinese medicines. Curr. Top. Med. Chem., 2008, 8, 1656-1665.
28. Wang, J.F.; Wei, D.Q.; Chou, K.C. Pharmacogenomics and personalized use of drugs. Curr. Top. Med. Chem., 2008, 8, 1573-1579.
29. Chen, J.; Shen, B. Computational Analysis of Amino Acid Mutation: a Proteome Wide Perspective. Curr. Proteomics, 2009, 6, 228-234.
30. Chou, K.C. Pseudo amino acid composition and its applications in bioinformatics, proteomics and system biology. Curr. Proteomics, 2009, 6, 262-274.
31. Giuliani, A.; Di Paola, L.; Setola, R. Proteins as Networks: A Mesoscopic Approach Using Haemoglobin Molecule as Case Study. Curr. Proteomics, 2009, 6, 235-245.
32. González-Díaz, H.; Prado-Prado, F.; Pérez-Montoto, L.G.; Duardo-Sánchez, A.; López-Díaz, A. QSAR models for proteins of parasitic organisms, plants and human guests: theory, applications, legal protection, taxes, and regulatory issues. Curr. Proteomics, 2009, 6, 214-227.
33. Ivanciuc, O. Machine learning Quantitative Structure-Activity Relationships (QSAR) for peptides binding to Human Amphiphysin-1 SH3 domain. Curr. Proteomics, 2009, 4, 289-302.
34. Pérez-Montoto, L.G.; Prado-Prado, F.; Ubeira, F.M.; González-Díaz, H. Study of parasitic infections, cancer, and other diseases with mass-spectrometry and quantitative proteome-disease relationships. Curr. Proteomics, 2009, 6, 246-261.
35. Torrens, F.; Castellano, G. Topological charge-transfer indices: from small molecules to proteins. Curr. Proteomics, 2009, 204-213.
36. Vázquez, J.M.; Aguiar, V.; Seoane, J.A.; Freire, A.; Serantes, J.A.; Dorado, J.; Pazos, A.; Munteanu, C.R. Star graphs of protein sequences and proteome mass spectra in cancer prediction. Curr. Proteomics, 2009, 6, 275-288.
37. Chou, K.C. Graphic rule for drug metabolism systems. Curr. Drug Metab., 2010, 11, 369-378.
38. Garcia, I.; Diop, Y.F.; Gomez, G. QSAR & complex network study of the HMGR inhibitors structural diversity. Curr. Drug Metab., 2010, 11, 307-314.
39. Gonzalez-Diaz, H. Network topological indices, drug metabolism, and distribution. Curr. Drug Metab., 2010, 11, 283-284.
40. Gonzalez-Diaz, H.; Duardo-Sanchez, A.; Ubeira, F.M.; Prado-Prado, F.; Perez-Montoto, L.G.; Concu, R.; Podda, G.; Shen, B. Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr. Drug Metab., 2010, 11, 379-406.
41. Khan, M.T. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Curr. Drug Metab., 2010, 11, 285-295.
42. Martinez-Romero, M.; Vazquez-Naya, J.M.; Rabunal, J.R.; Pita-Fernandez, S.; Macenlle, R.; Castro-Alvarino, J.; Lopez-Roses, L.; Ulla, J.L.; Martinez-Calvo, A.V.; Vazquez, S.; Pereira, J.; Porto-Pazos, A.B.; Dorado, J.; Pazos, A.; Munteanu, C.R. Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network. Curr. Drug Metab., 2010, 11, 347-368.
43. Mrabet, Y.; Semmar, N. Mathematical methods to analysis of topology, functional variability and evolution of metabolic systems based on different decomposition concepts. Curr. Drug Metab., 2010, 11, 315-341.
44. Wang, J.F.; Chou, K.C. Molecular modeling of cytochrome P450 and drug metabolism. Curr. Drug Metab., 2010, 11, 342-346.
45. Zhong, W.Z.; Zhan, J.; Kang, P.; Yamazaki, S. Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation. Curr. Drug Metab., 2010, 11, 296-306.
46. Concu, R.; Podda, G.; Ubeira, F.M.; Gonzalez-Diaz, H. Review of QSAR Models for enzyme classes of drug targets: theoretical background and applications in parasites, hosts, and other organisms. Curr. Pharm. Des., 2010, 16, 2710-2723.
47. Estrada, E.; Molina, E.; Nodarse, D.; Uriarte, E. Structural contributions of substrates to their binding to P-Glycoprotein. A TOPS-MODE approach. Curr. Pharm. Des., 2010, 16, 2676-2709.
48. Garcia, I.; Fall, Y.; Gomez, G. QSAR, Docking, and CoMFA Studies of GSK3 inhibitors. Curr. Pharm. Des., 2010, 16, 2666-2675.
49. González-Díaz, H. QSAR and complex networks in pharmaceutical design, microbiology, parasitology, toxicology, cancer, and neurosciences. Curr. Pharm. Des., 2010, 16, 2598-2600.
50. Gonzalez-Diaz, H.; Romaris, F.; Duardo-Sanchez, A.; Perez-Mototo, L.G.; Prado-Prado, F.; Patlewicz, G.; Ubeira, F.M. Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, aplications, and legal issues. Curr. Pharm. Des., 2010, 16, 2737-2764.
51. Marrero-Ponce, Y.; Casanola-Martin, G.M.; Khan, M.T.; Torrens, F.; Rescigno, A.; Abad, C. Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMDCARDD method to the elucidation of new compounds. Curr. Pharm. Des., 2010, 16, 2601-2624.
52. Munteanu, C.R.; Fernandez-Blanco, E.; Seoane, J.A.; Izquierdo-Novo, P.; Rodriguez-Fernandez, J.A.; Prieto-Gonzalez, J.M.; Rabunal, J.R.; Pazos, A. Drug discovery and design for complex diseases through QSAR computational methods. Curr. Pharm. Des., 2010, 16, 2640-2655.
53. Roy, K.; Ghosh, G. Exploring QSARs with extended topochemical atom (ETA) indices for modeling chemical and drug toxicity. Curr. Pharm. Des., 2010, 16, 2625-2639.
54. Speck-Planche, A.; Scotti, M.T.; de Paulo-Emerenciano, V. Current Pharmaceutical. Design of antituberculosis drugs: future perspectives. Curr. Pharm. Des., 2010, 16, 2656-2665.
55. Vazquez-Naya, J.M.; Martinez-Romero, M.; Porto-Pazos, A.B.; Novoa, F.; Valladares-Ayerbes, M.; Pereira, J.; Munteanu, C.R.; Dorado, J. Ontologies of drug discovery and design for neurology, cardiology and oncology. Curr. Pharm. Des., 2010, 16, 2724-2736.
56. Chiş, O.; Dumitru, O.; Concu, R.; Shen, B. Reviewing yeast network and report of new stochastic-credibility cell cycle models. Curr. Bioinform., 2011, 6, 35-43.
57. Dave, K.; Banerjee, A. Bioinformatics analysis of functional relations between CNPs regions. Curr. Bioinform., 2011, 6, 122-128.
58. Duardo-Sanchez, A.; Patlewicz, G.; González-Díaz, H. A review of network topological indices from chem-bioinformatics to legal sciences and back. Curr. Bioinform., 2011, 6, 53-70.
59. García, I.; Fall, Y.; Gómez, G. Trends in bioinformatics and chemoinformatics of vitamin D analogues and their protein targets. Curr. Bioinform., 2011, 6, 16-24.
60. Ivanciuc, T.; Ivanciuc, O.; Klein, D.J. Network-QSAR with reaction poset quantitative superstructure-activity relationships (QSSAR) for PCB chromatographic properties. Curr. Bioinform., 2011, 6, 25-34.
61. Prado-Prado, F.; Escobar-Cubiella, M.; García-Mera, X. Review of bioinformatics and QSAR studies of β-secretase inhibitors. Curr. Bioinform., 2011, 6, 3-15.
62. Riera-Fernández, P.; Munteanu, C.R.; Pedreira-Souto, N.; Duardo-Sanchez, A.; González-Díaz, H. Definition of Markov-Harary invariants and review of classic topological indices and databases of biology, parasitology, technology, and social-legal networks. Curr. Bioinform., 2011, 6, 94-121.
63. Speck-Planche, A.; Cordeiro, M.N.D.S. Application of bioinformatics for the search of novel anti-viral therapies: rational design of anti-herpes agents. Curr. Bioinform., 2011, 6, 81-93.
64. Wan, S.B.; Hu, L.L.; Niu, S.; Wang, K.; Cai, Y.D.; Lu, W.C.; Chou, K.C. Identification of multiple subcellular locations for proteins in budding yeast. Curr. Bioinform., 2011, 6, 71-80.
65. Bhattacharjee, B.; Jayadeepa, R.M.; Banerjee, S.; Joshi, J.; Middha, S.K.; Mole, J.P.; Samuel, J. Review of complex network and gene ontology in pharmacology approaches: mapping natural compounds on potential drug target colon cancer network. Curr. Bioinform., 2011, 6, 44-52.
66. Wang, X.; Yang, W.; Xu, X.; Zhang, H.; Li, Y.; Wang, Y. Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. Curr. Med. Chem., 2010, 17, 2788-2803.
67. Musmuca, I.; Caroli, A.; Mai, A.; Kaushik-Basu, N.; Arora, P.; Ragno, R. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. J. Chem. Inf. Model., 2010, 50, 662-676.
68. Ryu, K.; Kim, N.D.; Choi, S.I.; Han, C.K.; Yoon, J.H.; No, K.T.; Kim, K.H.; Seong, B.L. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorg. Med. Chem., 2009, 17, 2975-2982.
69. Patel, P.D.; Patel, M.R.; Kaushik-Basu, N.; Talele, T.T. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors. J. Chem. Inf. Model., 2008, 48, 42-55.
70. Kim, J.; Kim, K.S.; Kim, D.E.; Chong, Y. Identification of novel HCV RNA-dependent RNA polymerase inhibitors using pharmacophore-guided virtual screening. Chem. Biol. Drug Des., 2008, 72, 585-591.
71. Cao, H.; Cao, R.; Zhang, H.; Zheng, X.; Gao, D. Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3DQSAR and molecular docking studies. Curr. Med. Chem., 2008, 15, 1462-1477.
72. Di Santo, R.; Fermeglia, M.; Ferrone, M.; Paneni, M.S.; Costi, R.; Artico, M.; Roux, A.; Gabriele, M.; Tardif, K.D.; Siddiqui, A.; Pricl, S. Simple but highly effective three-dimensional chemicalfeature-based pharmacophore model for diketo acid derivatives as hepatitis C virus RNA-dependent RNA polymerase inhibitors. J. Med. Chem., 2005, 48, 6304-6314.
73. Frecer, V.; Kabelac, M.; De Nardi, P.; Pricl, S.; Miertus, S. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus. J. Mol. Graph. Model., 2004, 22, 209-220.
74. Li, X.; Zhang, W.; Qiao, X.; Xu, X. Prediction of binding for a kind of non-peptic HCV NS3 serine protease inhibitors from plants by molecular docking and MM-PBSA method. Bioorg. Med. Chem., 2007, 15, 220-226.
75. [Lead Questtm Compound Libraries. http://leadquest.tripos.com/
76. Kubinyi, H. QSAR: Hansch Analysis and Related Approaches, VCH Publishers: Weinheim, New York, Basel, Cambridge, Tokyo, 1993.
77. van de Waterbeemd, H. Chemometrics Methods in Molecular Design, VCH Publishers: Weinheim, New York, Basel, Cambridge, Tokyo, 1995.
78. van de Waterbeemd, H. Advanced Computer-Assisted Techniques in Drug Discovery, VCH Publishers: Weinheim, New York, Basel, Cambridge, Tokyo, 1995.
79. Gonzalez-Diaz, H.; Munteanu, C.R. Topological Indices for Medicinal Chemistry, Biology, Parasitology, Neurological and Social Networks, Transworld Research Network: Kerala, 2010.
80. Bonchev, D.; Rouvray, D.H. Complexity in Chemistry, Biology, and Ecology, Springer Science+Business Media, Inc: New York, 2005.
81. Dehmer, M.; Emmert-Streib, F. Analysis of Complex Networks. From Biology to Linguistics, WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, 2009.
82. Gupta, S.P.; Samanta, S.; Patil, V.M. A 3D-QSAR study on a series of benzimidazole derivatives acting as hepatitis C virus inhibitors: application of kNN-molecular field analysis. Med. Chem., 2010, 6, 87-90.
83. Wei, H.Y.; Lu, C.S.; Lin, T.H. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques. J. Mol. Graph. Model., 2008, 26, 1131-1144.
84. Nurbo, J.; Peterson, S.D.; Dahl, G.; Helena Danielson, U.; Karlen, A.; Sandstrom, A. Beta-amino acid substitutions and structurebased CoMFA modeling of hepatitis C virus NS3 protease inhibitors. Bioorg. Med. Chem., 2008, 16, 5590-5605.
85. Lei, B.; Du, J.; Li, S.; Liu, H.; Ren, Y.; Yao, X. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors. J. Comput. Aided Mol. Des., 2008, 22, 711-725.
86. Lara, J.; Wohlhueter, R.M.; Dimitrova, Z.; Khudyakov, Y.E. Artificial neural network for prediction of antigenic activity for a major conformational epitope in the hepatitis C virus NS3 protein. Bioinformatics, 2008, 24, 1858-1864.
87. Fontaine, F.; Pastor, M.; Zamora, I.; Sanz, F. Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors. J. Med. Chem., 2005, 48, 2687-2694.
88. Speck-Planche, A.; Scotti, M.T.; Emerenciano, V.P.; García-López, A.; Molina-Pérez, E.; Uriarte, E. Designing novel antitrypanosomal agents from a mixed graph-theoretical substructural approach. J. Comput. Chem., 2010, 31, 882-894.
89. Speck-Planche, A.; Scotti, M.T.; García-López, A.; Emerenciano, V.P.; Molina-Pérez, E.; Uriarte, E. Design of novel antituberculosis compounds using graph-theoretical and substructural approaches. Mol. Divers., 2009, 13, 445-458.
90. Viswanadhan, V.N.; Ghose, A.K.; Revankar, G.R.; Robins, R.K. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci., 1989 29, 163-172.
91. Viswanadhan, V.N.; Reddy, M.R.; Bacquet, R.J.; Erion, M.D. Assessment of methods used for predicting lipophilicity: application to nucleosides and nucleoside bases. J. Comput. Chem., 1993, 14, 1019-1026
92. Estrada, E.; Matamala, A.R. Generalized topological indices. Modeling gas-phase rate coefficients of atmospheric relevance. J. Chem. Inf. Model., 2007, 47, 794-804.
93. Estrada, E.; Gonzalez, H. What are the limits of applicability for graph theoretic descriptors in QSPR/QSAR? Modeling dipole moments of aromatic compounds with TOPS-MODE descriptors. J. Chem. Inf. Comput. Sci., 2003, 43, 75-84.
94. Estrada, E.; Molina, E.; Perdomo-Lopez, I. Can 3D structural parameters be predicted from 2D (topological) molecular descriptors? J. Chem. Inf. Comput. Sci., 2001, 41, 1015-1021.
95. Estrada, E.; Molina, E. Novel local (fragment-based) topological molecular descriptors for QSPR/QSAR and molecular design. J. Mol. Graph. Model., 2001, 20, 54-64.
96. Estrada, E.; Gutierrez, Y.; Gonzalez, H. Modeling diamagnetic and magnetooptic properties of organic compounds with the TOSSMODE approach. J. Chem. Inf. Comput. Sci., 2000, 40, 1386-1399.
97. Estrada, E. A computer-based approach to describe the 13C NMR chemical shifts of alkanes by the generalized spectral moments of iterated line graphs. Comput. Chem., 2000, 24, 193-201.
98. Estrada, E.; Gutierrez, Y. Modeling chromatographic parameters by a novel graph theoretical sub-structural approach. J. Chromatogr. A., 1999, 858, 187-199.
99. Estrada, E.; Uriarte, E.; Molina, E.; Simon-Manso, Y.; Milne, G.W. An integrated in silico analysis of drug-binding to human serum albumin. J. Chem. Inf. Model., 2006, 46, 2709-2724.
100. Vilar, S.; Estrada, E.; Uriarte, E.; Santana, L.; Gutierrez, Y. In silico studies toward the discovery of new anti-HIV nucleoside compounds through the use of TOPS-MODE and 2D/3D connectivity indices. 2. Purine derivatives. J. Chem. Inf. Model., 2005, 45, 502-514.
101. Estrada, E. Application of a novel graph-theoretic folding degree index to the study of steroid-DB3 antibody binding affinity. Comput. Biol. Chem., 2003, 27, 305-313.
102. Estrada, E.; Vilar, S.; Uriarte, E.; Gutierrez, Y. In silico studies toward the discovery of new anti-HIV nucleoside compounds with the use of TOPS-MODE and 2D/3D connectivity indices. 1. Pyrimidyl derivatives. J. Chem. Inf. Comput. Sci., 2002, 42, 1194-1203.
103. Estrada, E.; Uriarte, E. Recent advances on the role of topological indices in drug discovery research. Curr. Med. Chem., 2001, 8, 1573-1588.
104. Estrada, E.; Uriarte, E.; Montero, A.; Teijeira, M.; Santana, L.; De Clercq, E. A novel approach for the virtual screening and rational design of anticancer compounds. J. Med. Chem., 2000, 43, 1975-1985.
105. Estrada, E.; Peña, A. In silico studies for the rational discovery of anticonvulsant compounds. Bioorg. Med. Chem., 2000, 8, 2755-2770.
106. Estrada, E.; Pena, A.; Garcia-Domenech, R. Designing sedative/hypnotic compounds from a novel substructural graphtheoretical approach. J. Comput. Aided Mol. Des., 1998, 12, 583-595.
107. Estrada, E.; Molina, E. Automatic extraction of structural alerts for predicting chromosome aberrations of organic compounds. J. Mol. Graph. Model., 2006, 25, 275-288.
108. Estrada, E.; Patlewicz, G.; Chamberlain, M.; Basketter, D.; Larbey, S. Computer-aided knowledge generation for understanding skin sensitization mechanisms: the TOPS-MODE approach. Chem. Res. Toxicol., 2003, 16, 1226-1235.
109. Estrada, E.; Uriarte, E. Quantitative structure--toxicity relationships using TOPS-MODE. 1. Nitrobenzene toxicity to Tetrahymena pyriformis. SAR QSAR Environ. Res., 2001, 12, 309-324.
110. Estrada, E.; Molina, E.; Uriarte, E. Quantitative structure-toxicity relationships using TOPS-MODE. 2. Neurotoxicity of a noncongeneric series of solvents. SAR QSAR Environ. Res., 2001, 12, 445-459.
111. Estrada, E. Structure-mutagenicity relationships in 2-furylethylene derivatives. A molecular orbital study of the role of nitro groups. Mutat. Res., 1998, 420, 67-75.
112. Helguera, A.M.; Perez-Machado, G.; Cordeiro, M.N.D.S.; Combes, R.D. Quantitative structure-activity relationship modelling of the carcinogenic risk of nitroso compounds using regression analysis and the TOPS-MODE approach. SAR QSAR Environ. Res., 2010, 21, 277-304.
113. Helguera, A.M.; Gonzalez, M.P.; Cordeiro, M.N.D.S.; Perez, M.A.C. Quantitative structure-carcinogenicity relationship for detecting structural alerts in nitroso compounds: species, rat; sex, female; route of administration, gavage. Chem. Res. Toxicol., 2008, 21, 633-642.
114. Helguera, A.M.; Gonzalez, M.P.; M.N.D.S.C.; Perez, M.A. Quantitative structure carcinogenicity relationship for detecting structural alerts in nitroso-compounds. Toxicol. Appl. Pharmacol., 2007, 221, 189-202.
115. Estrada, E. Edge adjacency relationship and a novel topological index related to molecular volume. J. Chem. Inf. Comput. Sci., 1995, 35, 31-33.
116. Estrada, E. Spectral moments of the edge adjacency matrix in molecular graphs. 3. Molecules containing cycles. J. Chem. Inf. Comput. Sci., 1998, 38, 23-27.
117. Estrada, E. Spectral moments of the edge adjacency matrix in molecular graphs. 2. Molecules containing heteroatoms and QSAR applications. J. Chem. Inf. Comput. Sci., 1997, 37, 320-328.
118. Estrada, E. Spectral moments of the edge adjacency matrix in molecular graphs. 1. Definition and applications for the prediction of physical properties of alkanes. J. Chem. Inf. Comput. Sci., 1996, 36, 844-849.
119. [In ChEMBL Database (2010). Available at: http://www.ebi.ac.uk/chembldb/
120. The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals. In 14th ed.; O'Neill, M.J.; Heckelman, P.E.; Koch, C.B.; Roman, K.J., Eds. Whitehouse Station, NJ: Merck & Co., Inc: 2006.
121. Talete srl, DRAGON for Windows (Software for Molecular Descriptor Calculations). Version 5.3, 2005. Available at: http://www.talete.mi.it/dragon.htm.
122. [Estrada, E.; Gutiérrez, Y., MODESLAB 1.5. © 2002-2004. Available at: www.modeslab.com.
123. Prado-Prado, F.J.; Uriarte, E.; Borges, F.; Gonzalez-Diaz, H. Multitarget spectral moments for QSAR and Complex Networks study of antibacterial drugs. Eur. J. Med. Chem., 2009, 44, 4516-4521.
124. Prado-Prado, F.J.; de la Vega, O.M.; Uriarte, E.; Ubeira, F.M.; Chou, K.C.; Gonzalez-Diaz, H. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg. Med. Chem., 2009, 17, 569-575.
125. Prado-Prado, F.J.; Borges, F.; Uriarte, E.; Perez-Montoto, L.G.; Gonzalez-Diaz, H. Multi-target spectral moment: QSAR for antiviral drugs vs. different viral species. Anal. Chim. Acta, 2009, 651, 159-164.
126. Prado-Prado, F.J.; Borges, F.; Perez-Montoto, L.G.; Gonzalez-Diaz, H. Multi-target spectral moment: QSAR for antifungal drugs vs. different fungi species. Eur. J. Med. Chem., 2009, 44, 4051-4056.
127. Munteanu, C.R.; Vazquez, J.M.; Dorado, J.; Sierra, A.P.; Sanchez-Gonzalez, A.; Prado-Prado, F.J.; Gonzalez-Diaz, H. Complex network spectral moments for ATCUN motif DNA cleavage: first predictive study on proteins of human pathogen parasites. J. Proteome. Res., 2009, 8, 5219-5228.
128. Prado-Prado, F.J.; Gonzalez-Diaz, H.; de la Vega, O.M.; Ubeira, F.M.; Chou, K.C. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg. Med. Chem., 2008, 16, 5871-5880.
129. Gonzalez-Diaz, H.; Prado-Prado, F.J. Unified QSAR and networkbased computational chemistry approach to antimicrobials, part 1: multispecies activity models for antifungals. J. Comput. Chem., 2008, 29, 656-667.
130. Prado-Prado, F.J.; Gonzalez-Diaz, H.; Santana, L.; Uriarte, E. Unified QSAR approach to antimicrobials. Part 2: predicting activity against more than 90 different species in order to halt antibacterial resistance. Bioorg. Med. Chem., 2007, 15, 897-902.
131. Santana, L.; Uriarte, E.; Gonzalez-Diaz, H.; Zagotto, G.; Soto-Otero, R.; Mendez-Alvarez, E. A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J. Med. Chem., 2006, 49, 1149-1156.
132. STATISTICA 6.0 (Data Analysis Software System). StatSoft, Inc., 2001.
133. Hanley, J.A.; McNeil, B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 1982, 143, 29-36.